PT - JOURNAL ARTICLE AU - Lin, Gloria AU - Hein, David M. AU - Liu, Po-Hong AU - Singal, Amit G. AU - Sanford, Nina N. TI - Screening Implications for Distribution of Colorectal Cancer Subsite by Age AID - 10.1101/2023.07.18.23292663 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.18.23292663 4099 - http://medrxiv.org/content/early/2023/07/23/2023.07.18.23292663.short 4100 - http://medrxiv.org/content/early/2023/07/23/2023.07.18.23292663.full AB - Objectives The effectiveness of colonoscopy to reduce colorectal cancer (CRC) mortality is extrapolated from cohort studies in the absence of randomized controlled trial (RCT) data, whereas flexible sigmoidoscopy is supported by RCT data and may be easier to implement in practice. We characterized the anatomic distribution of CRC to determine the proportion that is visible with sigmoidoscopy.Methods Patients with a primary diagnosis of colorectal adenocarcinoma were identified in the Surveillance, Epidemiology, and End Results program (2000-2020). Tumors from the rectum to descending colon were categorized as visible by sigmoidoscopy, whereas more proximal tumors as requiring colonoscopy. Differential prognosis between tumor locations, stratified by age groups and stage, were assessed using overall restricted mean survival time (RMST) at 2, 5, and 10 years.Results Among 309,466 patients, 58% had tumors visible by sigmoidoscopy, including 73% of those under age 50 (OR 2.10, 95%CI 2.03-2.16 age <45, OR 2.20, 95%CI 2.13-2.27 age 45-49 versus age >50). Male sex (OR 1.54, 95%CI 1.51-1.56) and Asian or Pacific Islander race (OR 1.60, 95%CI 1.56-1.64) were also positively associated with tumors visualizable by sigmoidoscopy. Across age groups, for local disease, RMST was comparable for tumors visible versus not visible on sigmoidoscopy. For regional and metastatic cancer, patients with tumors visible by sigmoidoscopy had improved RMST versus those with more proximal tumors.Conclusions Most CRC arise in locations visible by flexible sigmoidoscopy. Flexible sigmoidoscopy should be considered as a viable option for CRC screening, particularly in younger patients unwilling or unable to undergo colonoscopy.Competing Interest StatementAGS has served as a consultant or on advisory boards for Exact Sciences, Universal Dx, Roche, Freenome, and GRAIL; PHL, DMH, GL and NNS have no conflicts to disclose relevant to the manuscript.Funding StatementNational Institutes of Health (T32DK007745), Dedman Scholar in Clinical Care Award, and Simmons Comprehensive Cancer Center Early Onset Colorectal Cancer GrantAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Test***I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at github.com/DavidHein96/seer-sigmoidoscopy https://www.github.com/DavidHein96/seer-sigmoidoscopy